Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2018 1
2019 5
2020 4
2021 2
2022 7
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Nuñez NG, et al. Among authors: kreutmair s. Med. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. Med. 2023. PMID: 36693381 Free article.
High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity.
Nuñez NG, Schmid J, Power L, Alberti C, Krishnarajah S, Kreutmair S, Unger S, Blanco S, Konigheim B, Marín C, Onofrio L, Kienzler JC, Costa-Pereira S, Ingelfinger F; InmunoCovidCba; InViV working group; Pasinovich ME, Castelli JM, Vizzotti C, Schaefer M, Villar-Vesga J, Mundt S, Merten CH, Sethi A, Wertheimer T, Lutz M, Vanoaica D, Sotomayor C, Gruppi A, Münz C, Cardozo D, Barbás G, Lopez L, Carreño P, Castro G, Raboy E, Gallego S, Morón G, Cervi L, Acosta Rodriguez EV, Maletto BA, Maccioni M, Becher B. Nuñez NG, et al. Among authors: kreutmair s. Nat Immunol. 2023 Jun;24(6):941-954. doi: 10.1038/s41590-023-01499-w. Epub 2023 Apr 24. Nat Immunol. 2023. PMID: 37095378 Free PMC article.
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.
Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Gonzalo Núñez N, Alberti C, da Costa Pereira S, Merten CH, Power L, Weiss M, Böke C, Pfeifer D, Marks R, Bertz H, Wäsch R, Ihorst G, Gentner B, Duyster J, Boerries M, Andrieux G, Finke J, Becher B, Vago L, Zeiser R. Apostolova P, et al. Among authors: kreutmair s. Br J Haematol. 2023 Oct;203(2):264-281. doi: 10.1111/bjh.19007. Epub 2023 Aug 4. Br J Haematol. 2023. PMID: 37539479
Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates.
Ingelfinger F, Kramer M, Lutz M, Widmer CC, Piccoli L, Kreutmair S, Wertheimer T, Woodhall M, Waters P, Sallusto F, Lanzavecchia A, Mundt S, Becher B, Schreiner B. Ingelfinger F, et al. Among authors: kreutmair s. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 8;10(2):e200087. doi: 10.1212/NXI.0000000000200087. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36754834 Free PMC article.
Preexisting comorbidities shape the immune response associated with severe COVID-19.
Kreutmair S, Kauffmann M, Unger S, Ingelfinger F, Núñez NG, Alberti C, De Feo D, Krishnarajah S, Friebel E, Ulutekin C, Babaei S, Gaborit B, Lutz M, Jurado NP, Malek NP, Göpel S, Rosenberger P, Häberle HA, Ayoub I, Al-Hajj S, Claassen M, Liblau R, Martin-Blondel G, Bitzer M, Roquilly A, Becher B. Kreutmair S, et al. J Allergy Clin Immunol. 2022 Aug;150(2):312-324. doi: 10.1016/j.jaci.2022.05.019. Epub 2022 Jun 16. J Allergy Clin Immunol. 2022. PMID: 35716951 Free PMC article.
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.
Kreutmair S, Unger S, Núñez NG, Ingelfinger F, Alberti C, De Feo D, Krishnarajah S, Kauffmann M, Friebel E, Babaei S, Gaborit B, Lutz M, Jurado NP, Malek NP, Goepel S, Rosenberger P, Häberle HA, Ayoub I, Al-Hajj S, Nilsson J, Claassen M, Liblau R, Martin-Blondel G, Bitzer M, Roquilly A, Becher B. Kreutmair S, et al. Immunity. 2021 Jul 13;54(7):1578-1593.e5. doi: 10.1016/j.immuni.2021.05.002. Epub 2021 May 9. Immunity. 2021. PMID: 34051147 Free PMC article.
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.
Kreutmair S, Unger S, Núñez NG, Ingelfinger F, Alberti C, De Feo D, Krishnarajah S, Kauffmann M, Friebel E, Babaei S, Gaborit B, Lutz M, Jurado NP, Malek NP, Goepel S, Rosenberger P, Häberle HA, Ayoub I, Al-Hajj S, Nilsson J, Claassen M, Liblau R, Martin-Blondel G, Bitzer M, Roquilly A, Becher B. Kreutmair S, et al. Immunity. 2022 Feb 8;55(2):366-375. doi: 10.1016/j.immuni.2022.01.015. Immunity. 2022. PMID: 35139354 Free PMC article. No abstract available.
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML.
Charlet A, Kappenstein M, Keye P, Kläsener K, Endres C, Poggio T, Gorantla SP, Kreutmair S, Sänger J, Illert AL, Miething C, Reth M, Duyster J, Rummelt C, von Bubnoff N. Charlet A, et al. Among authors: kreutmair s. Leukemia. 2022 Mar;36(3):701-711. doi: 10.1038/s41375-021-01462-4. Epub 2021 Nov 8. Leukemia. 2022. PMID: 34750506 Free PMC article.
22 results